Arbutus Biopharma Corp 8-K

What Happened
Arbutus Biopharma Corporation (with licensee Genevant Sciences GmbH) announced that on February 17, 2026 the U.S. District Court for the District of Delaware issued a memorandum and order in their litigation against Moderna Inc. and a Moderna affiliate. The case alleges infringement of U.S. Patent Nos. 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; and 11,141,378 in the manufacture and sale of Moderna’s COVID‑19 vaccine, mRNA‑1273. The court’s memorandum and order addresses motions for summary judgment and motions to exclude expert testimony; the memorandum is attached to the 8‑K as Exhibit 99.1.

Key Details

• Court action dated: February 17, 2026 (U.S. District Court, District of Delaware).
• Parties: Plaintiffs — Arbutus Biopharma Corporation and licensee Genevant; Defendants — Moderna Inc. and a Moderna affiliate.
• Subject: Alleged infringement relating to Moderna’s mRNA‑1273 COVID‑19 vaccine and six asserted U.S. patents (listed above).
• Filing: The court’s memorandum and order is filed as Exhibit 99.1 to the Form 8‑K.

Why It Matters
A district-court ruling on summary judgment and expert testimony can materially affect the strength, timing and potential outcome of a patent case — including damages, injunctive relief, or settlement dynamics. Investors should review the attached memorandum (Exhibit 99.1) for specifics of the court’s rulings and monitor future court filings for developments that could impact Arbutus’s legal position and potential financial recovery.